JV

Super Religare Laboratories Ties up with Rosetta

Rosetta's miRview tests can offer patients and physicians new insights on cancer

Rosetta Genomics, Limited, a leading developer of microRNA-based molecular diagnostics, and Super Religare Laboratories Limited (SRL), India's largest diagnostics network, recently announced that they have signed an exclusive distribution agreement for Rosetta Genomics' three currently-available diagnostic tests. Under the agreement, SRL will market Rosetta Genomics' miRview tests in India, Saudi Arabia, Qatar, and the UAE. Samples will be sent from SRL's territories to Rosetta Genomics' Philadelphia-based CLIA-certified laboratory for analysis. The agreement also envisages joint cooperation and collaboration between the two companies to conduct field trials for development of tests and assays an exchange of information for development of new technologies and leading edge diagnostic solutions. The Rosetta Genomics tests that will be distributed by SRL in India include miRview mets (to accurately identify the primary tumor site in patients with metastatic cancer); miRview squamous (this differentiates squamous from non-squamous, non-small cell lung cancer (NSCLC) patients) and miRview meso (to differentiate mesothelioma, a cancer connected to asbestos exposure, from other carcinomas in the lung).

EH News Bureau